Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 5, 2004, Pages 485-488

  McCollum, A David ^a,d,e   Kulke, Matthew H ^b,c   Ryan, David P ^d   Clark, Jeffrey W ^d   Shulman, Lawrence N ^b,c   Mayer, Robert J ^b,c   Bartel, Sylvia ^b   Fuchs, Charles S ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Islet cell carcinoma; Pancreatic endocrine tumor; Streptozocin

Indexed keywords

DOXORUBICIN; GASTRIN; GLUCAGON; INSULIN; STREPTOZOCIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALOPECIA; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE TUMOR; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PANCREAS ISLET CELL CARCINOMA; REVIEW; SURVIVAL TIME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; STREPTOZOCIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 5644266174     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000135343.06038.eb     Document Type: Review

References (13)

1. Eriksson B, Arnberg H, Lindgren PG, et al. Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med. 1990;228:103-113.
2. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663-666.
3. Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am. 2001;81:527-542.
4. di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer. 1996;77:402-408.
5. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244-248.
6. Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interfer-on-alpha- 2a. A study by the Italian Trials in Medical Oncology Group. Cancer. 1993;72:3099-3105.
7. Anderson JV, Bloom SR. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet. 1987;1:97.
8. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol. 1996;7:453-463.
9. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189-1194.
10. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-523.
11. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86:944-948.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.